Optune / EF-32 (TRIDENT)
Newly Diagnosed Glioblastoma
Phase 3Active
Key Facts
About Novocure
Novocure is a commercial-stage oncology company with a mission to extend survival in aggressive cancers through its innovative Tumor Treating Fields (TTFields) therapy. Its core achievement is the successful development and regulatory approval of TTFields for glioblastoma and, more recently, locally advanced pancreatic cancer, validating its unique physics-based mechanism. The company's strategy is to methodically expand TTFields into large, underserved solid tumor indications through a focused clinical pipeline while leveraging its commercial infrastructure and deep scientific expertise.
View full company profileTherapeutic Areas
Other Newly Diagnosed Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| LAM561 (idroxioleic acid/2-OHOA) | Laminar Pharmaceuticals | Phase 2b/3 |